PHARMACEUTICAL PREPARATION CONTAINING A GESTAGEN, AND KIT AND METHOD FOR TREATING ENDOMETRIOSIS USING THE PREPARATION

• US 20080214512A1
• Filed: 02/27/2008
• Published: 09/04/2008
• Est. Priority Date: 03/01/2007
• Status: Abandoned Application

• Current Assignee: Bayer Schering Pharma AG (Bayer AG)
• Original Assignee: Bayer Schering Pharma AG (Bayer AG)
• Inventors: Zimmermann, Holger, Wasserfall, Annemarie, Seitz, Christian
• Application Number:
  US12/037,990
• Publication Number:
  US 20080214512A1
• Time in Patent Office: Days
• US Class Current: 514/170
• CPC Class Codes: A61K 31/57 substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The pharmaceutical preparation for treating endometriosis contains at least 28, preferably 30, daily dose units, each of which contain dienogest, cyproterone acetate, or chlormadinone acetate at a daily dose that is at most twice that required to inhibit ovulation together with one or more pharmaceutical aids and/or carriers. The daily dose units are administered in a method of prophylaxis and/or therapy of endometriosis continuously during a time interval of at least 169 days or 25 weeks, preferably more than two years. The method effectively reduces endometriosis and associated pain, while undesirable side effects including bone density decrease are reduced or eliminated.

Claims

1. A pharmaceutical preparation for treating endometriosis, said pharmaceutical preparation comprising a daily dose of a gestagen with anti-androgenic activity, which is up to twice that for inhibiting ovulation, and one or more pharmaceutically acceptable aids and/or carriers.

2. The pharmaceutical preparation as defined in claim 1, in which said gestagen is dienogest, cyproterone acetate, or chlormadinone acetate.

3. The pharmaceutical preparation as defined in claim 2, in which said daily dose is 2 mg of said dienogest, an equivalent amount of said cyproterone acetate, or an equivalent amount of said chlormadinone acetate.

4. The pharmaceutical preparation as defined in claim 3, which comprises a package unit and at least 28 separately packaged and individually removable daily dose units contained in the package unit, and in which said daily dose units each consist of 2 mg of said dienogest, said equivalent amount of said cypropterone acetate, or said equivalent amount of said chlormadinone acetate and said one or more pharmaceutically acceptable aids and/or carriers.

5. The pharmaceutical preparation as defined in claim 4, wherein said package unit contains 30 of said separately packaged and individually removable daily dose units.

6. The pharmaceutical preparation as defined in claim 4, wherein said gestagen and said daily dose units are selected for prophylaxis and/or therapy of said endometriosis by continuous administration of said daily dose units during a time interval of at least 169 days or at least 25 weeks.

7. The pharmaceutical preparation as defined in claim 6, wherein said time interval is more than 2 years.

8. The pharmaceutical preparation as defined in claim 1, which does not negatively affect bone metabolism and thus reduce bone density.

9. The pharmaceutical preparation as defined in claim 1, in which said gestagen and said daily dose are selected so that said bone metabolism is not negatively affected and bone density is not reduced.

10. The pharmaceutical preparation said defined in claim 1, and in the form of tablets, capsules, sugar-coated tablets, wafers, transdermal therapy systems, ampoules, suppositories, gels, ointments, implants, vaginal rings, or nasal sprays.

11. A kit comprising containing at least 28 daily dose units of a pharmaceutical preparation for treating endometriosis, wherein each of said at least 28 daily dose units comprises a gestagen with anti-androgenic activity at a daily dose that is up to twice that for inhibiting ovulation and one or more pharmaceutically acceptable aids and/or carriers.

12. The kit as defined in claim 11, containing 28 of said daily dose units.

13. The kit as defined in claim 11, containing 30 of said daily dose units.

14. The kit as defined in claim 11, wherein said gestagen is dienogest, cyproterone acetate, or chlormadinone acetate and said daily dose is 2 mg of said dienogest, said equivalent amount of said cypropterone acetate, or said equivalent amount of said chlormadinone.

15. A method of treating endometriosis, said method comprising administering a pharmaceutical preparation containing at least one gestagen with anti-androgenic activity at a daily dose amounting to up to twice that for inhibiting ovulation.

16. The method as defined in claim 15, wherein said at least one gestagen component is dienogest, cyproterone acetate, or chlormadinone acetate.

17. The method as defined in claim 16, wherein said daily dose is 2 mg of said dienogest, an equivalent amount of said cyproterone acetate, or an equivalent amount of said chlormadinone acetate.

18. The method as defined in claim 15, wherein said administering comprises continuous administration of said daily dose of said at least one gestagen for a time interval of at least 169 days or at least 25 weeks.

19. The method as defined in claim 18, wherein said time interval is more than 2 years.

20. The method as defined in claim 15, wherein said administering comprises administration of said daily dose of said at least one gestagen to an individual suffering from said endometriosis in order to reduce said endometriosis.

21. The method as defined in claim 15, wherein said administering comprises administration of said daily dose of said at least one gestagen to an individual to prevent occurrence of said endometriosis.

22. The method as defined in claim 15, wherein said at least one gestagen and said daily dose are selected so that said administering has no negative effect on bone metabolism and thus does not reduce bone density.

23. The method as defined in claim 15, wherein said administering comprises administration of a pharmaceutical preparation containing said daily dose of said at least one gestagen and one or more pharmaceutically acceptable aids and/or carriers, and wherein said pharmaceutical preparation is in the form of tablets, capsules, sugar-coated tablets, wafers, transdermal therapy systems, ampoules, suppositories, gels, ointments, implants, vaginal rings, or nasal sprays.

24. A method of making a pharmaceutical preparation for treating endometriosis, said pharmaceutical preparation comprising a package unit containing at least 28 daily dose units, and wherein each of said daily dose units contains at least one gestagen at a daily doses up to twice that required for inhibiting ovulation and one or more pharmaceutically acceptable aids and/or carriers, and wherein said at least one gestagen is dienogest, cyproterone acetate, or chlormadinone acetate.